{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:11:27Z","timestamp":1740161487265,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11010-024-05098-7","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T12:02:27Z","timestamp":1725019347000},"page":"1403-1406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cThe unbearable lightness\u201d of the primary end point in clinical trials"],"prefix":"10.1007","volume":"480","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1252-7120","authenticated-orcid":false,"given":"A. J.","family":"Marian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"5098_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/01.cir.29.5s4.iv-3","volume":"30","author":"E Braunwald","year":"1964","unstructured":"Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG (1964) Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 30:3\u2013119. https:\/\/doi.org\/10.1161\/01.cir.29.5s4.iv-3","journal-title":"Circulation"},{"key":"5098_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-i","volume":"62","author":"AA Geisterfer-Lowrance","year":"1990","unstructured":"Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG (1990) A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62:999\u20131006. https:\/\/doi.org\/10.1016\/0092-8674(90)90274-i","journal-title":"Cell"},{"key":"5098_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D, Investigators E-Hs (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"key":"5098_CR4","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Dungen HD, Garcia-Pavia P, Hagege AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP, Investigators S-H (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390:1849\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2401424","journal-title":"N Engl J Med"},{"key":"5098_CR5","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","volume":"128","author":"AJ Marian","year":"2021","unstructured":"Marian AJ (2021) Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res 128:1533\u20131553. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318346","journal-title":"Circ Res"},{"key":"5098_CR6","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H, Rogers CS, Gorham JM, Wong FL, Morck MM, Seidman JG, Ruppel KM, Irving TC, Cooke R, Green EM, Spudich JA (2018) Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA 115:E8143\u2013E8152. https:\/\/doi.org\/10.1073\/pnas.1809540115","journal-title":"Proc Natl Acad Sci USA"},{"key":"5098_CR7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, Gonzalez-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simoes M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD, Investigators A-BT (2023) Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 389:1553\u20131565. https:\/\/doi.org\/10.1056\/NEJMoa2300757","journal-title":"N Engl J Med"},{"key":"5098_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC, Investigators AT-C (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390:132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"5098_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC, Committees ST-HT, Investigators (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"5098_CR10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ, Committees ST-HDT, Investigators (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390:1394\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"5098_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.cell.2012.03.029","volume":"149","author":"CE Grueter","year":"2012","unstructured":"Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R, Olson EN (2012) A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149:671\u2013683. https:\/\/doi.org\/10.1016\/j.cell.2012.03.029","journal-title":"Cell"},{"key":"5098_CR12","doi-asserted-by":"publisher","first-page":"e011548","DOI":"10.1161\/CIRCHEARTFAILURE.123.011548","volume":"17","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Palomares JFR, Sinagra G, Barriales-Villa R, Lakdawala NK, Gottlieb RL, Goldberg RI, Elliott P, Lee P, Li H, Angeli FS, Judge DP, MacRae CA, Investigators R-D (2024) REALM-DCM: a phase 3, multinational, randomized, placebo-controlled trial of ARRY-371797 in patients with symptomatic LMNA-related dilated cardiomyopathy. Circ Heart Fail 17:e011548. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011548","journal-title":"Circ Heart Fail"},{"key":"5098_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154\u2013156. https:\/\/doi.org\/10.1038\/ng1161","journal-title":"Nat Genet"},{"key":"5098_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS, Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"5098_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, Committee D-HT, Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05098-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:17:36Z","timestamp":1740057456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["5098"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05098-7","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"type":"print","value":"0300-8177"},{"type":"electronic","value":"1573-4919"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}